華潤醫藥(03320.HK)3款產品中選藥品集中採購
格隆匯1月20日丨華潤醫藥(03320.HK)發佈公告,該集團有3款產品分別於中國全國藥品集中採購招標或聯盟地區藥品集中採購中擬中選,分別為鋁碳酸鎂咀嚼片、阿奇黴素片及鹽酸特拉唑嗪片。若後續簽訂採購合同並實施,將有利於該等產品擴大其市場覆蓋和銷售,提升市場競爭力,對集團未來經營業績產生積極的影響。
目前,該集團已與聯合採購辦公室就該等產品分別簽訂適用的《全國藥品集中採購擬中選品種備忘錄》及《聯盟地區藥品集中採購擬中選品種備忘錄》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.